Mobile devices to detect early pneumonitis in stage III NSCLC patients on durvalumab. - ON TRAX
Study identifier:D4194C00008
ClinicalTrials.gov identifier:NCT04381494
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
Medical condition
Unresectable Stage III NSCLC
Phase
Phase 4
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
18 Years - 130 Years
Date
Study Start Date: 27 Apr 2020
Primary Completion Date: 27 Jan 2022
Study Completion Date: 27 Jan 2022
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other
Verification:
Verified 01 May 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: Observational/Other Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions. | - |
